An attempt to induce transient immunosuppression pre-erythrocytapheresis in a girl with sickle cell disease, a history of severe delayed hemolytic transfusion reactions and need for hip prosthesis

Hematology Reports

Volumn 5, Issue 2, 2013, Pages 36-38

  Cattoni, Alessandro ^a   Cazzaniga, Giovanni ^a   Perseghin, Paolo ^a   Zatti, Giovanni ^a   Gaddi, Diego ^a   Cossio, Andrea ^a   Biondi, Andrea ^a   Corti, Paola ^a   Masera, Nicoletta ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Alloimunization; Avascular necrosis of femoral head; Erythrocytapheresis; Rituximab; Sickle cell disesase

Indexed keywords

BILIRUBIN; CD20 ANTIGEN; ERYTHROPOIETIN; HEMOGLOBIN E; HEMOGLOBIN S; HYDROXYUREA; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PROTEIN ANTIBODY; RITUXIMAB;

ADOLESCENT; ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY TITER; APHERESIS; ARTICLE; BLOOD COMPATIBILITY; BLOOD GROUP DUFFY SYSTEM; BLOOD TRANSFUSION REACTION; BRAIN ISCHEMIA; CASE REPORT; COOMBS TEST; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; ERYTHROCYTAPHERESIS; ERYTHROCYTE TRANSFUSION; FEMALE; FEMUR HEAD NECROSIS; FOLLOW UP; HARRIS HIP SCORE; HEMOGLOBINURIA; HEMOLYTIC ANEMIA; HUMAN; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; TOTAL HIP PROSTHESIS; TREATMENT CONTRAINDICATION;

EID: 84879953331     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2013.e11     Document Type: Article

References (15)

1. Rosse W, Gallagher D, Kinney T, et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990;76:1431-7.
2. Talano JAM, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003;111:e661.
3. Bhattacharyya N, Wayne AS, Kevy SV, Shamberger RC. Perioperative management for cholecystectomy in sickle cell disease. J Pediatr Surg 1993;28:72-75.
4. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995;27:206-213.
5. Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Raccomandazioni per la gestione della malattia drepanocitica in Italia. 2012. Available from: http://www.aieop.org/files/files_htmlarea/pubblicazioni_tiziana/GL/globulo_rosso/documenti/14.02.2011%20raccomandazioni%20drepanocitosi%20Russo%20rev.%201.pdf. Accessed on: June 2013.
6. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-3861.
7. Sigler E, Shvidel L, Yahalom V, et al. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion - severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab. Transfusion 2009;49:1370-1374.
8. Bley C, Aravechia MG, Hamerschlak N, et al. Autoantibody formation after alloimmunization inducing bystander immune hemolysis. Immunohematology 2009;25:9-12.
9. Noizat-Pirenne F, Bachir D, Chadebech P, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica 2007;92:132-5.
10. Behmeyer. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol 2010;85:91-92.
11. Stübgen JP. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol 2008;204:1-12.
12. Kumar S, Benseler SM, Kirby-Allen M, Silverman E. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009;123:159.
13. Wang RH, Phillips G, Medof ME, Mold C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest 1993;92:1326-1335.
14. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
15. Petz LD. Bystander immune cytolysis. Transfus Med Rev 2006; 20:110-140.